Table. 1.

List of metabolic inhibitors targeting prostate cancer.

S. NO	Drug	Target	Mechanism of action
1	Metformin	AMPK, mTORC1, ETC complex 1	Inhibits tumour proliferation, confers survival benefit in retrospective prostate tumour cohort135–137
2	MSDC-0160	Mitochondrial pyruvate carrier	Decreases mitochondrial oxygen consumption, depletes TCA cycle intermediates in hormone-responsive and castration-resistant AR+ models of prostate cancer39
3	IACS-010759	ETC complex-I	Inhibits proliferation, depletes macromolecule pools and induces apoptosis in PTEN-null mouse models of prostate cancer138
4	Fatostatin	SREBP–SCAP	Inhibits lipogenesis, blocks tumour growth and metastatic spread in metastatic and non-metastatic autochthonous models of mouse prostate cancer93
5.	MT 63-78	AMPK	Inhibits cell proliferation, induces mitotic arrest and apoptosis; activates AMPK and suppresses lipogenesis in hormone-responsive and castration-resistant AR+ and AR– models of prostate cancer139
6	IPI-9119	FASN	FASN inhibition through IP-9119 leads to reduced protein expression and decreased transcriptional activity of full-length AR as well as splice variant AR V7. Thus, antagonises growth through metabolic reprogramming in hormone-responsive and castration-resistant AR+ models of prostate cancer.86

AMPK 5’ AMP-activated protein kinase, AR androgen receptor, ETC electron transport chain, mTORC mammalian target of rapamycin complex, SREBP–SCAP sterol regulatory-element binding protein–SREBP cleavage-activating protein.